EVENITY is approved in U.S. for the treatment of osteoporosis in postmenopausal women at high risk for fracture.3 EVENITY is also approved in Japan and South Korea for the treatment of osteoporosis ...
The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a ...
UCB and Amgen have brought their bone-boosting drug Evenity back to US regulators for review, following an initial rejection in July last year. UCB and Amgen have brought their bone-boosting drug ...
THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was ...
The #FierceMadness drug name champion is Evenity. The Amgen osteoporosis drug triumphed over BeiGene’s Brukinsa in a 2,811 to 1,692 match to win the title of best drug name, as chosen by FiercePharma ...
Amgen and UCB’s Evenity (romosozumab) has been recommended for use by the NHS in England and Wales by the National Institute for Health and Care Excellence (NICE). The drug can be used to treat ...
Amgen will head into its FDA advisory committee meeting for new osteoporosis drug Evenity next week comforted by a first approval for the bone-building drug in Japan. The biotech already has the ...
Amgen Inc. AMGN and partner UCB SA UCBJF announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab). Amgen is looking to ...
The final contest is set. Amgen’s Evenity will face BeiGene’s Brukinsa for the title of best drug name in the #FierceMadness 2020 tournament. Both drugs handily dispatched opponents in the Final Four ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results